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‘Normalizing’ the malignant phenotype of luminal
breast cancer cells via alpha(v)beta(3)-integrin
Hanan Abu-Tayeh1, Keren Weidenfeld1, Alisa Zhilin-Roth1, Sagi Schif-Zuck1, Sonja Thaler2, Cristina Cotarelo3, Tuan Z Tan4,
Jean P Thiery5,6, Jeffrey E Green7, Geula Klorin8, Edmond Sabo8, Jonathan P Sleeman2,9, Maty Tzukerman10 and Dalit Barkan*,1
Reestablishing tissue organization of breast cancer cells into acini was previously shown to override their malignant phenotype. In
our study, we demonstrate that alpha(v)beta(3) integrin (Int-αvβ3), previously shown to play a role in cancer progression, promoted
differentiation and growth arrest of organoids derived from luminal A breast cancer cells grown in their relevant three-dimensional
microenvironment. These organoids differentiated into normal-like acini resembling a benign stage of breast tissue. Likewise, we
demonstrate that Int-αvβ3 is selectively expressed in the epithelium of the benign stage of breast tissues, and is lost during the
early stages of luminal A breast cancer progression. Notably, the organoids’ reversion into normal-like acini was mediated by
cancer luminal progenitor-like cells expressing both EpCAMhighCD49flowCD24+ and Int-αvβ3. Furthermore, downregulation of
Notch4 expression and downstream signaling was shown to mediate Int-αvβ3-induced reversion. Intriguingly, when luminal A
breast cancer cells expressing Int-αvβ3 were injected into a humanized mouse model, differentiated tumors developed when
compared with that generated by control cells. Hence, our data suggest that promoting differentiation of luminal A breast cancer
cells by signaling emanating from Int-αvβ3 can potentially promote ‘normalization’ of their malignant phenotype and may prevent
the malignant cells from progressing.
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Integrins are a large family of αβ heterodimeric cell surface
receptors that mediate cell–cell and cell–extracellular matrix
interactions1,2 and play an important role during cancer
progression. Of these receptors, αvβ3 integrin (Int-αvβ3) was
shown to be highly expressed in several cancer types.3,4
However, its contribution to breast cancer progression has
been un-conclusive given conflicting results in the literature
concerning the outcome of inhibiting Int-αvβ3 expression/
activity on breast tumor cells.5,6 Recently, low concentrations
of RGD-mimetic Int-αvβ3 and integrin-αvβ5 (Int-αvβ5) inhibi-
tors were shown to paradoxically stimulate tumor growth and
angiogenesis.5,7,8 Moreover, regulation of tumor progression
by tumor and stromal β3 integrin (Int-β3) were shown to vary in
breast cancer models.9 Here we demonstrate that Int-αvβ3 is
selectively expressed in the epithelium of the benign stage of
breast tissues and is lost during early stages of luminal A
(positive for estrogen and progesterone receptors) breast
cancer progression. Hence, these surprising results suggest
that Int-β3 expressionmight maintain the differentiated state of
premalignant tissue via its engagement with its restrictive
normal microenvironment, the latter acting as a gatekeeper
during neoplastic progression.10 Therefore, we hypothesized
that Int-β3 re-expression in luminal A breast cancer cells will
promote their differentiation in conjunction with their
microenvironment.
We found that re-expression of Int-β3 by human luminal
breast cancer cell lines MCF-7 and T47D promotes their
cancer luminal progenitor-like cells (CLPs) to revert into
growth-arrested acinar-like organoids resembling normal
breast tissue when cultured in a three-dimensional (3D)
reconstituted basement membrane extract (BME)11 mimicking
the components of the normal basement membrane.12 This
reversion was mediated by downregulation of Notch4 expres-
sion and its downstream signaling. Intriguingly, tumors
developed by MCF-7-Intβ3 cell were highly differentiated
compared with MCF-7 tumors, grown in an in vivo humanized
mouse model.13,14 All together, these findings demonstrate for
the first time to our knowledge that CLPs, which are present in
luminal A breast cancer cell lines and tissues,15 can be
induced to differentiate into acinar-like organoids via expres-
sion of Int-αvβ3 in the 3D system and in vivo to a more
differentiated phenotype.
Results
Int-β3 is expressed in early hyperplastic breast tissue
and can promote differentiation of luminal A breast
cancer cells in the 3D BME system. We examined the
expression of Int-β3 in paraffin-embedded biopsy tissues of
normal breast and luminal A; usual ductal hyperplasia (UDH),
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low-grade ductal carcimoma in situ (DCIS), high-grade DCIS
and invasive ductal carcinoma grade 1 (IDC-G1) (Figures 1a
and b). Intriguingly, all UDH cases (14% of the luminal
epithelial cell/acinus) expressed Int-β3, which was confined
to the outer layer of the luminal epithelial cells comprising the
acinus (Figures 1b and c and Supplementary Figure S1A,
see red arrows). In contrast, Int-β3 expression was not
detected in normal breast tissue and rarely in low, high-grade
epithelium of DCIS and IDC-G1 samples (Figures 1b and c).
However, moderate to high expression of Int-β3 was detected
in the stroma of IDC-G1 samples (Figure 1b and
Supplementary Figure S1B, see black arrows). Thus, Int-β3
expression in the breast epithelial cells was lost on progres-
sion from benign to IDC-G1 stage. Hence, Int-β3 expression
Figure 1 Int-β3 is expressed in UDH of human breast tissue and its expression induces a 3D-differentiated phenotype on luminal breast cancer cells in vitro. (a) Scheme
demonstrating the different stages in breast cancer progression. (b) Paraffin-fixed tissue from normal and luminal A breast cancer patients representing different stages (4–5
cases of each stage) stained for Int-β3 expression (red) nuclei countered stained with hematoxilin (blue). Bars= 100 μm. (c) Intensity of staining and percentage of breast
epithelial cells expressing Int-β3 (frequency). (d–e) F-actin staining (green) of MCF-7 (d) and T47D cell lines (e) cultured for 40 days in the 3D BME system. Representative
confocal images, magnification × 40, bars= 50 μm
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may mediate engagement of the benign tissue with its
restrictive normal microenvironment, the latter being a gate-
keeper during neoplastic progression.10 Therefore, we tested
whether re-expression of Int-β3 in MCF-7 and T47D luminal A
breast cancer cell lines (Supplementary Figure S2) will
promote their differentiation. Int-β3 stably expressed in clones
of MCF-7 cells (MCF-7-Intβ3 #15 and #17) and pool of T47D
cell line were cultured in the 3D BME system. Intriguingly,
both cell lines stably expressing Int-β3 differentiated into an
acinar-like structure, similar to normal mammary tissue,
whereas control MCF-7-vec and T47D-vec cells formed
disorganized organoids (Figures 1d and e).
Luminal breast cancer cells expressing Int-αvβ are
enriched with putative cancer luminal progenitor-like
cells. Normal acini consist of luminal epithelial cells
surrounding the lumen and myoepithelial cells surrounding
the luminal cells. Both originate from mammary stem cells
and progenitor cells. Three distinct types of human breast
epithelial cell progenitors have been previously described:
luminal-restricted, myoepithelial-restricted and bipotent
progenitors.16–18 Int-β3 was recently found to serve as a cell
surface marker specifically identifying the mouse luminal
progenitors committed to terminally differentiate into the
luminal epithelial cells.19,20
Similar to primary breast tumors and breast cancer cell
lines, the MCF-7 and T47D cells consist of heterogeneous cell
populations, including cancer stem cells (CSC) and cancer
cells expressing markers of CLPs.15 Given previous studies
and our surprising results demonstrating that Int-β3 can
promote the differentiation of MCF-7 and T47D cell lines into
a normal-like acini in the 3D BME system, has prompted us to
test whether MCF-7-Intβ3 cells may be enriched with cancer
stem/progenitor-like cells that can commit and differentiate
into normal-like acini (Figure 2a). Therefore, MCF-7 cell lines
were grown as non-adherent mammospheres for two pas-
sages. MCF-7-Intβ3 cell lines exhibited a significant increase
in their sphere capacity formation (6–10-fold increase versus
MCF-vec cells, Figures 2b and c), indicating their potential
cancer stem/progenitor cell-like properties. Furthermore,
cilengtide inhibited the sphere formation potential of both
MCF-7-vec cells and, to a greater degree, MCF-7-Intβ3 cells
(Figure 2d). Given that cilengitide blocks Int-αvβ3 and Int-αvβ5
activity and that Int-αvβ5 is expressed in both cell lines (data
not shown), suggests that the sphere formation capacity of
MCF-7-Intβ3 cells is mediated partially by Int-αvβ3. Next, we
determined by flow cytometry analysis the distribution of
cancer stem/progenitor-like cells in both the control and Int-
αvβ3 expressing MCF-7 and T47D cell lines. Single cells were
dissociated from either 2D culture or secondary grown
mammospheres (enriching for stem/progenitor-like cells) and
were analyzed for the expression of (1) EpCAMneg/low
CD49fhigh and CD44high CD24low phenotype; shown to be
expressed by stem cells of normal and cancerous human
breast tissue and breast cancer cell lines;15,21–23 and for (2)
EpCAMposCD49fpos phenotype; shown to be expressed by
human luminal progenitor cells24 and to be present in MCF-7
and enriched in T47D cell lines.15 Our results demonstrate
the presence of three subpopulations of cells across the
cell lines; CSC and two subpopulations of cells with
EpCAMposCD49fpos phenotype: EpCAMhighCD49flow
(CLPslow) and EpCAMhighCD49fhigh (CLPshigh) phenotype
derived either from mammospheres (Figures 3a–c and e–g)
or from 2D cultures (Supplementary Figures S3A–C and
E–G). The CLPslow were the prominent subpopulation across
the different cell lines (Figures 3c, d, g and h; Supplementary
Figures S3C–D and G–H). In addition, significant increase in
CLPslow and significant decrease in CLPshigh cells was
apparent in both MCF-7-Intβ3 #17 and T47D-Intβ3 cells
(Figures 3c and d and Figures 3g and h, respectively;
Supplementary Figure S3G-H). Furthermore, CLPslow expres-
sing cells were all positive for CD24 expression (a luminal
progenitor marker24) across all cell lines derived frommammo-
spheres (Figures 3c and g) or from 2D culture (Supplementary
Figures S3C and G), further confirming their potential CLPs
phenotype. Importantly, within the EpCAMhighCD49flowCD24+
Int-β3+ cells derived from grownmammospheres ofMCF-7 and
T47D cell lines; 91–95% and 64% of the cells were positive for
Int-αVβ3 expression, respectively. Notably, the percentage of
CSCs expressing either the EpCAMneg/low CD49fhigh
(Figures 3d and h and Supplementary Figures S3D and H) or
CD44high CD24low phenotype (Supplementary Figure S4)
among the different cell lines did not increase and represented
a small subpopulation of the total cell population (o10%).
Hence, both cell lines non-expressing and expressing Int-αVβ3
were predominantly enriched with CLPslow. However, in cells
expressing Int-αVβ3 and grown as mammospheres there was
a significant increase in CLPslow.
Int-avβ3 expression in CLPslow promotes their differen-
tiation into acinar-like organoids in the 3D BME system.
Given that non-expressing and expressing Int-αvβ3 cells
were enriched with CLPslow, but only cell lines expressing Int-
αvβ3 differentiated in the 3D BME system, has led us to test
whether Int-αvβ3 expression commits CLPslow to differentiate
into acinar-like organoids. CLPslow subset either negative for
Int-αVβ3 expression (CLP-Int-αvβ3neg; derived from MCF-7-
vec and T47D-vec cell lines) or positive for Int-αVβ3
expression (CLP-Int-αVβ3pos; derived from MCF-7-Intβ3
#15/#17 and T47D-Intβ3 cell lines) were flow sorted either
from 2D culture or from non-adherent mammospheres and
were placed in the 3D BME system and scored for their
potential to differentiate (Figures 4a and 5a). CLP-Int-αvβ3pos
developed homogeneous spherical luminar-containing struc-
tures (Figures 4b and c, Figures 5b-d and Supplementary
Figure S5) with apical expression of MUC-1 by both cell lines
(Figures 4b and c middle panel, Figure 5b, white arrow) and
basal expression of laminin 5 by MCF-7-Intβ3 cells
(Figures 3b and c right panel, yellow arrow.) Notably, 35%
and 41% of CLP-Int-αvβ3pos derived either from MCF-7-Intβ3
or T47D-Intβ3 cells, respectively, differentiated (Figure 4d and
Figures 5d and e). Whereas, CLP-Int-αvβ3neg formed
disorganized cellular clusters (Figures 4b and c, Figure 5b–d
and Supplementary Figure S5). Furthermore, treatment of
CLP-Int-αvβ3pos with cilengitide significantly inhibited their
differentiation into acinar-like structures (twofold reduction)
compared with that of vehicle treated (Figures 4c and d).
Since these acinar-like structures are derived from CLPs that
were implicated previously as the source of basal-like breast
tumors (negative for estrogen progesterone and Her2
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Figure 2 Characterizing MCF-7 cell lines for their sphere rising potential. (a) Scheme demonstrating the hypothesis: expression of Int-αvβ3 in either CSC/CLPs will promote
their differentiation into normal acini in the 3D BME system. (b–d) Second generation of grown mammospheres from MCF-7 cell lines. (b) Light microscopy images (magnification
× 10). (c) Quantification of the number of mammospheres. (d) Quantification of mammospheres either untreated or treated with cilengitide (20 μM). Columns; mean, bars; STD;
n= 3; *P⩽ 0.05; **P⩽ 0.01 and ***P⩽ 0.001
Figure 3 Int-αvβ3 expression in MCF-7 and T47D cells promotes the enrichment of EpCAMhighCD49flowCD24+ subpopulation of cells. Cells derived from second generation
of grown mammopsheres of either (a–d) MCF-7 cell lines, or (e–h) T47D cell lines. (a and e) Histogram representing three cell populations with different levels of expression of
CD49f normalized to unstained cells. (b and f) Mean fluorescence intensity of CD49f expression in the different subpopulations. (c and g) Top panel: representative dot plot
showing CSC expressing EpCAMlowCD49fhigh, CLPs either expressing EpCAMhighCD49flow (CLPlow) or EpCAMhighCD49fhigh (CLPhigh) phenotype. Bottom panel (red square):
representative dot plot showing CLPlow subpopulation positive for CD24 expression. (d and h) Percentage of CSC, CLPlow and CLPhigh. Quantification was carried out with
FACSdiva software. Columns; mean, bars; STD; n= 3; *P⩽ 0.05, **P⩽ 0.01 ***P⩽ 0.001
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receptor24), we investigated whether these Int-αvβ3pos acini
retained their luminal phenotype. Indeed, flow sorted CLP-Int-
αVβ3pos isolated from either non-adherent mammospheres
(progenitors) or from 2D culture and cultured in the 3D BME
system (differentiated) (Figures 4e and f) expressed the
luminal markers GATA3 and estrogen receptor (ER).
0
10
20
30
40
50
60
70
80
90
100
vec #15 Intβ3 #17 Intβ3
%
 o
f c
el
ls
 e
xp
re
ss
in
g 
Ep
C
A
M
/C
D
49
f m
ar
ke
rs
MCF-7 cell lines
*
**
**
Ep
C
A
M
CD49f
C
D
24
MCF-7 vec MCF-7 #15 Intβ3 MCF-7 #17 Intβ3 
CSC
CLP CLP
CSC
CLP CLP
CSC
CLP CLP
CD49f
Ep
C
A
M
C
D
24
CSC
CLP
CLP
T47D vec T47D Pool-Intβ3 
CSC
CLP CLP
***
0
100
200
300
400
500
600
CD49f neg CD49f low CD49f highM
ea
n 
flu
or
es
ce
nc
e
in
te
ns
ity
MCF-7 cell lines
***
***
***
0
100
200
300
400
500
600
700
CD49f neg CD49f low CD49f high
M
ea
n 
flu
or
es
ce
nc
e
in
te
ns
ity
T47D cell lines
***
***
Mean fluorescence intensity
%
 o
f  
M
ax
CD49f
CD49f
CD49f
Mean fluorescence intensity
%
 o
f  
M
ax
0
10
20
30
40
50
60
70
80
 vec pool-Intβ3
%
 o
f c
el
ls
 e
xp
re
ss
in
g
Ep
C
A
M
/C
D
49
f m
ar
ke
rs
T47D cell lines
*
***
Differentiation of breast cancer cells via beta3-integrin
H Abu-Tayeh et al
5
Cell Death and Disease
Intriguingly, the polarized outer layer of cells comprising the
acini selectively expressed the milk protein β-casein in
absence of a lactogenic stimulus (Figures 4g–i and 5c). In
contrast, such a pattern of expression and localization were
absent in the cellular organoids derived from CLP-Int-αvβ3neg
(Figures 4i and 5c). These results suggest that expression of
Int-αvβ3 in CLPslow derived either from 2D culture or from
mammospheres can be redirected to differentiate into
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acinar-like structure reminiscent of the normal alveolar cells
comprising the breast tissue.
CLP-Int-avβ3pos differentiate into growth-arrested acinar-
like organoids resembling UDH. During normal morpho-
genesis, cell clearing in the luminal space is mediated by cell
death partly promoted by apoptosis.25–27 Indeed, at day 19 in
culture we observed cell death in the center of the organoids
(Supplementary Figure S6A-B), partly mediated by apoptosis
(Supplementary Figure S6C). Furthermore, these acini-like
structures were cell cycle arrested, depicted by significant
decrease in the percentage of proliferating cells within
each acini (Figures 6a and b) and significant increase in
cyclin-dependent kinase inhibitor p21 expression (Figures 6c
and d).
Importantly, nuclear size has been previously shown to
increase from benign to malignant breast tissue along with
disruption of the rounded architecture of the acini.28 Our
results demonstrate a significant decrease in average nuclear
size (P⩽ 0.01) comprising the differentiated acini, compared
with undifferentiated organoids (Supplementary Figure S7A,
lower panel). Furthermore, the average roundness values of
both differentiated acini (derived from either normal breast
MCF-10A cells or MCF-7-Intβ3 #17 cells) were similar and
significantly different from the average roundness value of the
non-differentiated organoids (derived from MCF-7-vec cells)
(Supplementary Figure S7B). Overall these results suggest
that MCF-7-Intβ3 #17 cells differentiated to a more benign
stage resembling early hyperplastic breast tissue when
cultured in the 3D BME system.
Int-β3 expression in MCF-7 tumors promotes their
differentiation in a hESC-based teratoma model. We
tested whether expression of Int-β3 in MCF-7 cells will
promote their differentiation in vivo within the microenviron-
ment of normal differentiated human cells, given that tumor
microenvironment has been shown to greatly influence
tumorigenicity properties. For this purpose, we generated
human teratomas derived from hESC in SCID/beige mice,
which comprised a wide variety of non-transformed differ-
entiated tissues of human origin.13,14 After 6 weeks either
MCF-7-Intβ3-GFP cells or MCF-7-vec-GFP cells were
injected into mature teratomas. Teratomas bearing tumors
were collected after 3–4 weeks and paraffin sections were
prepared and stained with H&E or subjected to immunohis-
tochemistry using anti-Intβ3 or anti-GFP antibodies. Immu-
nohistological analysis revealed that MCF-7-vec-GFP cells,
initially originating from pleural effusion of human breast
adenocarcinoma, similarly generated invasive tumors when
inculcated into the teratomas. Whereas, inoculated MCF-7-
Intβ3-GFP cells generated more differentiated tumors
depicted by formation of tubular structures with lumens,
significant reduction in nuclear pleomorphism, less hyper
chromatic nuclei and lower mitotic figures (Figure 6e and
Supplementary Figure S7C-D). Taken together, these results
suggest that MCF-7-Intβ3 tumors grown in the human
teratoma microenvironment were more differentiated com-
pared with MCF-7 tumors.
Int-αVβ3 promotes downregulation of Notch4 signaling.
Previous studies implicated the role of Notch4 signaling in
cell fate, such as differentiation of progenitor cells and
tumorgenesis, and that activation of Notch4 gene inhibited
mammary epithelial cell differentiation and promoted tumor
formation.29–31 This has prompted us to test whether
differentiating CLP-Int-αvβ3pos cells will inhibit Notch4 expres-
sion and its downstream signaling in the 3D BME system.
Importantly, Notch4 is activated upon its interaction with its
ligands leading to Notch4 cleavage. This results in release of
the active intracellular form of Notch4 (N4-ICD), which
translocates to the nucleus regulating transcription of
targeted genes such as Hey1.32 Therefore, we flow sorted
either the CLP-Int-αvβ3neg or CLP-Int-αvβ3pos (as described
in Figure 4a). Protein lysets were extracted from CLPs before
culturing them in the 3D BME system (designated progeni-
tors, Figure 7a) and after their differentiation in the 3D BME
system (designated differentiated, Figure 7b) once acini were
apparent (at day 30–40). In addition, protein was extracted
from the total subpopulations of cells derived from MCF-7-vec
and MCF-7-Intβ3 #17 cells grown in 2D culture (designated
2D, Figure 7a). Our results demonstrate that both the Notch4
and N4-ICD were highly expressed in MCF-7-vec cells in 2D
culture and in flow sorted CLP-Int-αvβ3neg, before and after
their culture in the 3D BME system. Whereas, Int-αvβ3
expression in both MCF-7 cells grown in 2D culture and in
CLPs inhibited the expression of both Notch4 and N4-ICD
(Figures 7a and b). This significant inhibition was maintained
after their differentiation in the 3D BME system (Figures 7b
and c) and was partially reversed by inhibiting Int-αvβ3
activity with cilengitide (Figures 7b and c). To further
evaluate the downstream signaling of Notch4, we looked for
the transcription regulation of Hey1. Our results demon-
strates a 50% significant reduction in Hey1 mRNA levels
in differentiating acinar-like organoids compared with that in
Figure 4 Int-αvβ3 expression and activity is required to commit CLPslow to differentiate into alveolar lineage in the 3D BME system. (a) Scheme demonstrating the sorting
from 2D culture/mammospheres of CLP-Int-αvβ3neg or CLP-Int-αvβ3pos cells and their culture in the 3D BME system. (b) CLP-Int-αvβ3pos/neg derived from 2D culture or (c)
derived from second generation of grown mammospheres either untreated or treated with cilengitide (40 μM) and cultured in the 3D BME system. Left panel: representative light
microscopy images (magnification × 20). Middle and right panel: representative confocal images of cross sections through the middle of organoids stained for MUC-1 (white
arrow), laminin 5 (yellow arrow) and nuclei (Dapi, blue). Magnification × 40 (zooming was adjusted accordingly to attain the whole cluster in the field of view), bar= 50 μm, n= 5.
(d) Percentage of differentiated organoids per field in the 3D BME culture (an average of 10 fields were scored) ***Pp0.001. (e) Semi-qPCR analysis of mRNA transcript levels of
GATA3 and ER in sorted CLP-Int-αvβ3pos/neg before (progenitor) and after culturing in the 3D BME system (differentiated). (f) W.B. analysis for the expression of GATA3 and ER in
CLP-Int-αvβ3pos/neg cultured in the 3D BME system. (g) Semi-qPCR analysis of mRNA transcript levels of β-casein in CLP-Int-αvβ3pos/neg cultured in the 3D BME system. (h) W.
B. analysis for the expression of β-casein in CLP-Int-αvβ3pos/neg cultured in the 3D BME system (n= 2). (i) Representative confocal images of z-stacks of organoids stained with
Dapi for nuclei (blue) for F-actin (green) and immunofluorescence staining for β-casein (red). Magnification × 40. Bars= 50 μm. Representative results; n= 3
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non-differentiating organoids in the 3D BME system
(Figures 7d and e). Overall, these results suggest that
differentiation of CLP-Int− αvβ3pos to normal acinar-like
organoids in the 3D BME system is mediated by down-
regulation of Notch4 signaling. Indeed, stable knockdown of
Notch4 and its activated form (N4-ICD) in MCF-7 cells by
shRNA targeting of Notch4 expression (Figures 8a and b)
was sufficient to promote their differentiation in the 3D BME
system (Figures 8c and d).
Discussion
Our results demonstrate that expression of Int-αvβ3, pre-
viously shown to play a role in tumor progression (reviewed in
ref. 33), can surprisingly promote differentiation of CLPslow in
conjunction with their microenvironment into (i) a precancer-
ous stage resembling human UDH when placed in the 3D
BME system (ii) and to a more differentiated phenotype when
introduced in vivo into a supportive microenvironment of
human origin. Furthermore, our results suggest that Int-αvβ3
may mediate this reversion by downregulating Notch4
signaling.
Ectopic expression and activation of Int-αvβ3 in luminal A
breast cancer cell lines preferentially expanded the prominent
CLPslow population when grown only as non-adherent
mammospheres. Similarly, the presence of EpCAMpos
CD49fpos (CLPs) subsets of cells in luminal A and B breast
cancer cell lines and tissues were reported previously.15
Interestingly, Int-αvβ3 re-expression in luminal A breast cancer
cell lines did not expand the CSCs population as was reported
for other types of cancers,34 thus suggesting that Int-αvβ3
diverse effect depends on cancer type and subtype.
Here we demonstrate that re-expression of Int-αvβ3 will
promote luminal A breast cancer cells to differentiate into
polarized acinar-like organoids containing a hollow lumen
when cultured in the 3D BME system. This differentiation was
not dependent on the expansion of CLPslow by Int-αvβ3
expression, but rather was dependent on their commitment to
differentiate via Int-αvβ3 expression. Moreover, Int-αvβ3
inhibition by cilengitide significantly reduced the number of
differentiated acini. Importantly, the formation of the acini was
mediated by cellular death due partly to apoptosis, as reported
during the normal morphogenesis of mammary acini.25–27 In
addition, our results demonstrate that these differentiated acini
retain their luminal phenotype (expressing ER, GATA3 and
MUC-1) and surprisingly displayed an alveolar phenotype with
milk protein β-casein expression confined to the outer
polarized layer of cells surrounding the hollow lumen with no
lactogenic stimulus. Interestingly, a recent report demon-
strated that Int-β3 is required for mouse mammary develop-
ment during pregnancy.35 However, in that model system Int-
β3 expression was required for the expansion of the
pregnancy-associated mammary stem cells.
Evidence supports the idea that disruption of cell-polarity
mechanisms promotes tumor initiation, thus suggesting a role
of cell and tissue polarity mechanisms as potential non-
canonical tumor suppressors.36,37 Several studies demon-
strated how interfering with adhesion molecules that are
aberrantly expressed in the cancer cells and the microenvir-
onmental context can redirect breast cancer cells to a normal-
like phenotype.12,21,38–41 Importantly, this reversion was
associated with growth arrest, similar to normal mammary
tissue.26,38 Concordantly, our results demonstrate that the
reversion of Int-αvβ3 expressing cells to normal-like acini
culminated in their growth arrest.
Similarly, a previous in vivo study demonstrated that
MCF-7-Intβ3 cells developed very small indolent tumors
compared with MCF-7 cells.42 To further characterize the
behavior of MCF-7-Intβ3 cells in the context of their
microenvironment, we utilized a tumor microenvironment
model on the basis of the potential of hESC to generate
teratomas in immunodeficient mice. This model provides an
in vivo humanized tumor microenvironment.13 Intriguingly, we
demonstrated that Int-β3 expression in MCF-7 cells in
conjunction with the teratoma microenvironment developed
more differentiated tumors compared with MCF-7-vec cells,
however, both cell lines retained their invasive properties as
was evident by histology and presence of dormant dissemi-
nated tumor cells in the lungs (data not shown). Taken
together, our results demonstrate that the composition of the
tumor microenvironment engaging with MCF-7-Intβ3 cells will
dictate the extent of their differentiation. Furthermore, our
findings suggest that complete halt of tumor progression may
require targeting the signaling pathways that mediate invasion
concomitantly with those promoting differentiation; such as
those emanating from Int-αvβ3.
Examination of the mechanisms responsible for this
differentiation revealed that Int-αvβ3 expression inhibited
Notch4 and N4-ICD expression and downstream signaling in
differentiating CLPslow derived from MCF-7 cells. Conversely,
inhibiting the function of Int-αvβ3 with cilengitide partially
restored Notch4 expression and activation leading to sig-
nificant reduction in the number of differentiated organoids.
Hence, these results suggest that inhibiting Notch4 in CLPslow
will promote their differentiation into a normal acinar-like
organoids in the 3D BME system. Indeed, we demonstrate
that knockdown of Notch4 expression in MCF-7 cells was
sufficient to promote their differentiation in the 3D BME
system. These findings are in concordance with previous
reports demonstrating that overexpression of the activated
Notch4 oncoprotein in normal breast epithelial cells abrogated
their normal morphogenesis in 3D culture.43 Furthermore,
knockdown of Notch4 in MCF-7 cells completely abolished
their ability to form tumors in the mouse mammary fat pad.44
Overall, the results described above suggest that Int-αvβ3
expression in CLPslow will promote their differentiation into
acinar-like organoids via downregulation of Notch4 expression
and downstream signaling, thus inhibiting tumor growth.
The reversion of the malignant phenotype to a more
differentiated or benign phenotype is the goal of differentiation
therapy and if successful, may change the prognosis of most
patients with recurrent cancer by decades. We demonstrated
that the acini arising from CLP-Int-αvβ3pos in the 3D BME
system resemble UDH – a benign stage of breast tissue.
Intriguingly, Int-αvβ3 is shown to be selectively expressed in
the epithelium of UDH of breast tissues, and is lost during early
stages of luminal A breast cancer progression. Whereas, in
the late stage Int-αvβ3 expression was mostly confined to the
stroma, the latter previously shown to play a role in cancer
progression.45 These surprising results differ from previous
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reports suggesting that tumoral expression of Int-αvβ3 plays a
role in tumor progression (reviewed in ref. 33). Importantly, we
have also conducted a meta-analysis of 3992 breast cancer
patient samples previously developed (Pubmed ID PMID:
23964924) and demonstrated that Int-β3 expression levels
cannot predict overall survival and disease-free survival of
luminal A breast cancer patients (Supplementary Figure S8).
These results may well reflect our observation of the spatial
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expression (epithelium versus stromal cells) and temporal
expression of Int-β3 in different stages of luminal A breast
cancer progression and suggest that our observations are
specific to luminal A breast cancer subtypes.
Taken together, our study demonstrates that CLPs of
luminal A breast cancer cells can be induced to differentiate
to a more benign phenotype in conjunction with their
microenvironment by promoting downstream signaling that
Figure 6 MCF-7-Intβ3 cells are growth arrested in the 3D BME system and differentiate in vivo. (a–d) MCF-7 cell lines cultured in the 3D BME system. (a) Left panel:
representative confocal image of cross section through the middle of an organoid (day 36) stained for Ki67 (white). Right panel: digital zooming of the selected area, white arrow
indicates Ki67 positive cells. (b) Quantification of the percentage of Ki67-positive cells within each cross section through the middle of the organoids. Twenty-five organoids of
each condition were scored. Bars= 50 μm. (c) W.B. analysis for the expression of p21 and its quantification normalized to GAPDH in the organoids (d); (n= 3) (e) Serial paraffin
section of teratomas injected with either MCF-7-vec-GFP or MCF-7-Intβ3-GFP cells. Paraffin section were subjected to H&E staining (magnification × 20), or subjected to either
GFP or Int-β3 staining (digital zooming of the selected area is presented). Representative images; n= 3
Figure 7 Inhibition of Notch4 signaling in differentiating MCF-7-Intβ3 cells. (a–b) W.B. analysis and (c) quantification of Notch4 and N4-ICD expression in a. Lysates collected
either directly from 2D culture (2D) or from CLPs derived from 2D culture of MCF-7-vec and MCF-7-Intβ3 (progenitor) and after their differentiation in the 3D BME system (b). (c)
Quantification of Notch4 (n= 3) and N4-ICD expression (n= 2) normalized to tubulin. (d) Semi-qPCR analysis of mRNA transcript levels of Hey1 in cells cultured in the 3D BME
system. (e) qPCR quantification of Hey1 mRNA levels; values were normalized to GAPDH (n= 2) (*P⩽ 0.05; **P⩽ 0.05 and ***P⩽ 0.001)
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Figure 8 Knockdown of Notch4 expression in MCF-7 cells promotes their differentiation into acinar-like organoids in the 3D BME system. Cells derived from 2D culture of
MCF-7-sh-non-target (sh-NT) and MCF-7-sh-Notch4 cell lines. (a) Semi-qPCR analysis for the knockdown of Notch4 expression. (b) W.B. analysis for the knockdown of N4-ICD
expression. (c–d) MCF-7-sh-NT and MCF-7-sh-Notch4 cells cultured in the 3D BME system for 32 days. (c) Left panel: representative light microscopy images (magnification
× 20). Middle panel: representative confocal images of the cross section through the middle of the organoids. Right panel: representative confocal images of z-stacks of organoids
stained with Dapi for nuclei (blue), F-actin (green). Magnification × 40. Bars= 50 μm. (d) Top panel: representative confocal images of the cross section through the middle of a
magnified portion of an acquired image at 31 mm2/field stained with F-actin (green). White arrowheads indicate differentiated organoids. Magnification × 10. Bars= 50 μm.
Bottom panel: table representing percentage of differentiated organoids/31 mm2 acquired field
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emanates from Int-αvβ3, such as inhibition of Notch4 signal-
ing. Promoting differentiation of luminal A breast cancer cells
by targeting Notch4 signaling may be an attractive target given
Notch4-restricted expression in normal tissue.46 Development
of selective monoclonal antibodies and/or potential use of
luteolin, recently shown to inhibit Notch4 signaling47 should be
considered for future treatment of recurring and/or endocrine-
resistant breast disease. Such an approach may provide the
means to maintain a chronic and dormant-like state of the
recurring breast disease and will hopefully extend patients
survival with minimal side effects.
Materials and Methods
Cell lines culture and reagents. MCF-10A cell were obtained from
Dr. Israel Vlodavsky (Technion Ins, Haifa, Israel) and were maintained as described
previously.48 MCF-7 and T47D cells were obtained from American Type Culture
Collection (ATCC) and were stably transected with pCDNA3-Intβ3 (a gift from Dr.
Newman PJ; The Blood Research Center of Southeastern Wisconsin Inc.). Clones
of MCF-7-Intβ3 and pool of T47D-Intβ3 were selected by G418 (Gold
Biotechnology, St. Louis, MO, USA) and were maintained in DMEM or RPMI
supplemented with 10% fetal bovine serum and antibiotics (Life Technologies,
Hertzliya Pituach, Israel), respectively. 3D cultures were carried out in growth factor-
reduced Cultrex Basement Membrane Extract (Trevigen, Inc., Gaithersburg, MD,
USA) 49 as previously described.48,50 Cilengitide, was a kind gift from Dr. Ronit
Satchi Fainaro (University of Tel Aviv). Immunofluorescent images were captured by
either Zeiss LSM 700 or by Nikon A1R confocal microscope.
Mammosphere assay. The different MCF-7 and T47D cell lines were
dissociated into single cells and plated on ultralow attachment 24-well plates
(Corning) (2000 cells/ml) as described previously.21 Quantification of the number of
mammospheres was done by light microscopy at magnification × 10 for counting all
mammospheres/field. Experiments were repeated three times with three
replicates each.
Flow cytometric analysis (FACS). Single cells were dissociated and were
characterized for Int-αvβ3− /+ expression (using anti-CD51/CD61-PE) and the gated
populations were further characterized for the expression of EpCAM (using anti-
EpCAM-APC), CD49f (using anti-CD49f-FITC) and CD24 (anti-CD24-PerCP) using
FACSCanto II (BD). For CSC characterization: CD44high (using anti-CD44-Brilliant
Violet 421TM) and CD24low (using anti-CD24-PerCP) expression was determined. All
antibodies were obtained from Biolegend (San Diego, CA, USA).
Quantitative RT-PCR. RNA was reversed-transcribed using the High Capacity
RNA-to-cDNA Kit (Applied Biosystems, Carlsbad, CA, USA). The cDNA was used
as a template for semi-quantitative and for quantitative PCR using the PCR Dream
Taq Mix (Thermo-scientific, Waltham, MA, USA) or the Fast SYBR Green Master
Mix kit, respectively. Analysis of gene expression was performed with the
StepOneTM and StepOnePlusTM Real-Time PCR detection system (Applied
Biosystems) using the relative standard curve method. The following PCR primers
(forward and reverse, respectively) for human GAPDH, GATA3 and Νοtch4 were
designed using the Integrated DNA Technologies Inc software. Human GAPDH: 5′-
ATGGGGAAGGTGAAGGTCG-3′ and 5′-GGGGTCATTGATGGCAACAATA-3′;
Human GATA3: 5′-GCCCCTCATTAAGCCCAAG-3′ and 5′-TTGTGGTGGTCTGAC
AGTTCG-3′; Human ER: 5′-AAGAGCTGCCAGGCCTGCC-3′ and 5′-TTGGCA
GCTCTCATGTCTCC-3′;51 Human Hey1: 5′-TGAGCTGAGAAGGCTGGTAC-3′ and
5′-ACCCCAAACTCCGATAGTCC-3′;52 Human β-casein: 5′-CCCTCAAATCCCAAA
ACTCA-3′ and 5′-GAGCAGAAGGGCTTGAACAG-3′;53 Human Notch4:
5′-GATGGGCTGGACACCTACAC-3′ and 5′-CACACGCAGTGAAAGCTACCA-3′.
Short hairpin RNA silencing experiments. MCF-7 cells were infected
with Mission shRNA lentiviral particles targeting either human Notch4 (sh-Notch4)
(Clone ID#TRCN0000426949) or with non-target shRNA (sh-NT) (Sigma Aldrich
Israel, Rehovot, Israel), selected with puromycin (2 μg/ml; Sigma) and maintained in
DMEM supplemented with 10% fetal bovine serum and antibiotics (Life
Technologies).
Immunoblot. Immunoblots were conducted as previously described.54 Speci-
fically, cells grown in 3D BME were extracted with ice cold PBS supplemented with
5 mM EDTA (1.5 h at 4°C on a shaker). Pellets were lysed in WCE (whole-cell
extract) buffer (25 mM Hepes, pH 7.7, 0.3M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.1% Triton X-100, 100 μg/ml PMSF and protease inhibitor cocktail (Roche, 1 : 100
dilution)). The proteins were separated by SDS-PAGE (8/10/12%) followed by
transfer on to a nitrocellulose membrane. The membranes were blocked with either
5% (w/v) non-fat dried skimmed milk powder in PBS supplemented with 0.05%
Tween20 (PBS-T) or with 5% BSA in TBST for 1 h at room temperature. Membrane
was then probed either with mouse anti-human GATA3 (1 : 500; Biolegend), mouse
anti-human ER (1 : 200), rabbit anti-human P21 (1 : 1000), rabbit anti-β-casein
(1 : 200), rabbit anti-tubulin (1 : 1000; Santa Cruz, Dallas, TX, USA), rabbit anti-
human Notch4 (1 : 400; Abcam, Cambridge, MA, USA), at 4°C overnight. Next,
Horseredish peroxidase-conjugated secondary antibodies to rabbit or mouse
immunoglobulin G (IgG) were used (1 : 10 000; Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) for 1 h at room temperature and washed
15 min × 3 with PBS-T. Western Bright ECL (Advansta, Menlo Park, CA, USA) was
added to the membrane for 30 s and analyzed using ImageQuant LAS-4000
analyzer (GE Healthcare Life Sciences, Pittsburgh, PA, USA) and ‘ImageQuant
LAS-4000’ software (GE Healthcare Life Sciences). Notably, Notch4 and N4-ICD
detection was obtained by 15 and 4–5 min exposure, respectively. Densitometry
analysis was performed using ImageQuant total lab-7 (GE Healthcare Life
Sciences) image analysis software.
Immunofluorescence staining in 3D culture. Immunofluorescence
staining for MUC-1, Laminin-5, β casein and Ki67 was carried out as described
previously54 with some modifications. The different cell lines, 7 × 103 cells/well on
the eight-chamber glass slide system were cultured in Cultrex growth factor-reduced
Basement Membrane Extract (BME: Trevigen, Inc) as described previously.48,50
Fixed cells were blocked with either 3% BSA or IF buffer (130 mM NaCl, 7 mM
Na2HPO4, 3.5 mM NaH2PO4, 7.7 mM NaN3, 0.1% BSA, 0.2% Triton X-100, 0.05%
Tween20) supplemented with 10% donkey serum for 1 h and incubated overnight at
4 °C with either antibody. The primary antibodies used were as follows: rabbit
monoclonal antibody to Ki67 (conjugated with FITC; 1:100), rabbit polyclonal
antibody to laminin 5 (1 : 500), rabbit antibody to MUC-1 (1 μg/ml) and rabbit
antibody to β-casein (5 μg/ml) from Abcam. The cells were washed three times with
PBS for 15 min each, and incubated for 60 min with donkey anti-rabbit conjugated
to Alexa Fluor 647 (Invitrogen, Carlsbad, CA, USA), washed as above, and mounted
with VECTASHIELD mounting medium with 4′, 6-diamidino-2-phenylindole (DAPI).
For F-actin staining, cells were incubated overnight with Alexa-Fluor 488 Phalloidin
(1 : 40) (Molecular Probes, Eugene, OR, USA), washed three times with PBS for
15 min each and mounted with VECTASHIELD mounting medium with DAPI.
Immunofluorescent images were captured by either Zeiss LSM 700 confocal laser
scanning microscope or Nikon A1R confocal microscope.
Paraffin biopsies. Paraffin biopsies from normal patients and from patients
with different stages of luminal A breast cancer were obtained from the Institute of
Pathology, Johannes Gutenberg University, Mainz. The local ethical review board
approved use of the tissue samples. Immunohistochemical staining for Int-β3
expression was carried out on the paraffin sections as described below.
Teratoma and tumor formation. SCID/beige mice were purchased from
Harlan Laboratories Ltd., Israel. The mice were housed under specific pathogen-
free conditions. The experimental protocols were approved by the committee for
cversight of animal experimentation at the Technion – Israel Institute of Technology,
Haifa, Israel.
Teratoma formation was carried out as previously described.13 Briefly
undifferentiated hESC clone H9.1 (46XX) were injected into the hindlimb musculature
of SCID/beige mice (~5 × 106 cells per injection). The formed teratoma was
composed of a wide variety of disorganized but normal differentiated human tissue
and structures, comprising differentiated cell types representing derivatives of all
three major embryonic lineages.55 At 6–7 weeks following initial injection of hESC,
4 × 106 of either MCF-7-vec-GFP or MCF-7-Intβ3-GFP cells were injected into the
teratoma and were allowed to grow for an additional 3–4 weeks. Teratomas were
collected and prepared for paraffin sections and immunohistochemistry staining for
Int-β3 and GFP expression was carried out as described below.
Immunohistochemical staining. Paraffin blocks were sectioned at 4 mm
thickness and were microwave pretreated in citrate buffer (pH 6.0) for antigen
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retrieval. Endogenous peroxidase activity was blocked using 3% H2O2 in methanol.
Sections were washed and blocked with goat serum for 1 h and incubated with
either the primary antibody for Int-β3 (1 : 250 for biopsies sections and 1 : 50 for
tetatoma sections; Abcam) or with primary antibody for GFP (1 : 500; Abcam)
overnight at 4 °C. Immunohistochemical detection was performed using the labeled
streptavidin biotin complex method (Histostain Plus Bulk Kit; Zymed Laboratories,
Inc., San Francisco, CA). AEC (3-amino-9-ethylcarbazole) was used as a
chromogen, and slides were counterstained with hematoxylin. The biopsies
sections were scored for the frequency and the intensity of Int-β3 staining by an
expert pathologist at Ramba Medical Center. The frequency of staining was
determined by counting the percentage of positive staining of epithelial cells for
Int-β3 expression per cluster and the intensity of staining was evaluated ranging
from 0–3.
Histomorphometry. Fluorescent and bright field images of the breast
organoids were analyzed with the Image Pro Plus 7 (Media Cybernetics, MA,
USA). The bright field images were measured for the total area of the breast tissue
organoids in Microns Square and their contour irregularity (colony roundness=
colony perimeter2/(4 x pi x colony area)). The area and the roundness are built in
parameters that were provided by the commercial program (Image Pro Plus). The
Image Pro Plus software automatically counted the DAPI images after finding the
appropriate threshold of the colored pixels. Only single intact nuclei were scored
(the range of nuclei size that was scored was ≥ 7⩽ 160). An average number of
255–324 nuclei were analyzed per cluster. The cells counts were expressed as
number of epithelial cells per acinus.
Statistical analysis. Student’s unpaired t-test was used for data analysis.
Comparison of the histomorphometric parametric variables between two groups
was done using unpaired student t-test after evaluating the variances using the
Leven’s test. Two tailed P-values of 0.05 or less were considered to be statistically
significant.
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